Sort
8,912 grants matching “sars cov 2”
An eco-friendly solution to workplace infection risk durng the COVID-19 pandemic and beyond.
$243,241Amir Khazaieli · Fathhome, Inc · R43 · FY2021 · OH
Bacteria and Lymphocyte Suppression in Periodontitis
$243,125Bruce J Shenker · University Of Pennsylvania · R01 · FY2020 · DE
Longitudinal cohort study of SARS-CoV2 sero-conversion in a malaria-endemic community in Western Kenya
$243,050Steve Myer Taylor · Duke University · R21 · FY2022 · AI
Promoting Health, Safety, and Recovery Training for COVID-19 Essential Workers and their Communities
$243,004David Turcotte · University Of Massachusetts Lowell · U45 · FY2021 · ES
Development of Antigen-based Vertical Flow Assay for the Rapid Detection of SARS-CoV-2, Influenza A/B, and RSV
$243,000Arunkumar Arumugam · Ai Biosciences, Inc. · R43 · FY2021 · IP
Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus
$243,000David Camerini · Immport Therapeutics, Inc. · R43 · FY2021 · IP
Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines
$243,000Darrick Albert Carter · Pai Life Sciences, Inc. · R43 · FY2021 · IP
Tuft Cells Modulate Macrophage Response Following Lung Viral Infection
$243,000Jianwen Que · Columbia University Health Sciences · R21 · FY2022 · AI
Defining the Impact of Per/Polyfluoroalkyl Substance Exposure on Susceptibility to SARS-CoV-2 Infection and Disease
$242,950Jennifer J Schlezinger · Boston University Medical Campus · R21 · FY2021 · ES
Environmental Factors Predicting Risk of Severe COVID Infection
$242,800Elizabeth Anne Regan · National Jewish Health · R21 · FY2021 · ES
COVID-19: immune response and systems vaccinology
$242,663Lothar Hennighausen · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Multivariate spatiotemporal models to quantify disparities in COVID-19 health outcomes
$242,655Brian Neelon · Medical University Of South Carolina · R21 · FY2022 · MD
Administrative Core
$242,550Clayton Yates · Tuskegee University · U54 · FY2021 · MD
Entry inhibition of SARS-CoV-2 by human LRRC15
$242,350Sanghyun Lee · Brown University · R21 · FY2024 · AI
SBIR Phase I: Regulation of Hyperinflammation and Cell Survival Under Hypoxia with NELL1/NV1: A Therapy for Severe Lung Tissue Damage in Viral Infections (COVID-19)
$242,342Cymbeline Culiat · Nellone Therapeutics, Inc. · · FY2021 · TIP
Determinants of Coronavirus Fidelity in Replication and Pathogenesis
$242,311Mark R Denison · Vanderbilt University · R01 · FY2015 · AI
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 Vaccines
$242,250Monica Gandhi · University Of California, San Francisco · R21 · FY2023 · AI
Impact of COVID-19 on disinfectant exposure and associated health effects.
$242,250Soo-Jeong Lee · University Of California, San Francisco · R21 · FY2021 · ES
Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and Disease
$242,250Judith A Woodfolk · University Of Virginia · R21 · FY2021 · AI
COORDINATING CENTER TO HELP ELIMINATE/REDUCE ORAL HEALTH INEQUALITIES IN CHILDREN
$242,250Stuart A Gansky · University Of California, San Francisco · U01 · FY2020 · DE
Rapid SARS-CoV-2 Spike Protein Neutralizing Antibody Tests for Evaluating COVID Vaccine-Generated Immunity
$242,132Suiqiong Li · Dl Adv-Tech, Llc · R43 · FY2021 · IP
Urgent Covid-19 Revision to the Center for High-Throughput Functional Annotation of Natural Products
$241,894John B Macmillan · University Of California Santa Cruz · U41 · FY2020 · AT
An Innovative Approach to Improving Asthma Control for World Trade Center Rescue and Recovery Workers through Telehealth Enriched Asthma Management (WTC-TEAM)
$241,799Erin Thanik · Icahn School Of Medicine At Mount Sinai · R21 · FY2021 · OH
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
$241,700Stefanie N. Vogel · University Of Maryland Baltimore · R21 · FY2021 · AI
Sex-Dependent Regulation of Host Factors Influencing SARS-CoV-2 Infection and COVID-19 Disease
$241,688Montserrat C Anguera · University Of Pennsylvania · R21 · FY2022 · AI